Welcome to CSNpharm! For Research Use Only!
JAK
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN18177 | ZM39923 | 273727-89-2 | ZM39923 is a Janus kinase inhibitor with IC50 of 10 nM |
| CSN18107 | WHI-P97 | 211555-05-4 | WHI-P97 is a rationally designed potent inhibitor of JAK-3 |
| CSN18721 | Upadacitinib | 1310726-60-3 | Upadacitinib is a selective JAK1 inhibitor with an IC50 of 43 nM. |
| CSN12405 | TG 101348 | 936091-26-8 | TG 101348 is an inhibitor of JAK2 with an IC of 6 nM and also inhibits related kinases FLT3, RET, and JAK3 with less potent activity, having IC values of 25, 17 and 169 nM, respectively. |
| CSN23146 | TC JL 37 | 1258294-34-6 | TCJL-37 is a potent TYK2 inhibitor. |
| CSN15697 | Solcitinib | 1206163-45-2 | Solcitinib is a highly selective JAK1 inhibitor with IC50 value of 9.8 nM, with much less potency against JAK1 and JAK2 with IC50 values 100nM. |
| CSN24499 | SAR-20347 | 1450881-55-6 | SAR-20347 is a TYK2 and JAK inhibitor with IC50 values of 0.6, 23, 26 and 41nM for TYK2, JAK1, JAK2 and JAK3, respectively. |
| CSN18612 | S-Ruxolitinib | 941685-37-6 | S-Ruxolitinib is the first potent, selective, JAK12 inhibitor to enter the clinic with IC50 of 3.3 nM2.8 nM, 130-fold selectivity for JAK12 versus JAK3. |
| CSN17456 | Ruxolitinib Sulfate | 1092939-16-6 | Ruxolitinib sulfate is the first potent, selective, JAK12 inhibitor to enter the clinic with IC50 of 3.3 nM2.8 nM, 130-fold selectivity for JAK12 versus JAK3. |
| CSN13499 | Ruxolitinib Phosphate | 1092939-17-7 | Ruxolitinib phosphate is a potent and selective JAK12 inhibitor to enter the clinic with IC50 of 3.3 nM2.8 nM, 130-fold selectivity for JAK12 versus JAK3. |
| CSN12394 | Ruxolitinib | 941678-49-5 | Ruxolitinib is the first potent, selective, JAK12 inhibitor to enter the clinic with IC50 of 3.3 nM2.8 nM, 130-fold selectivity for JAK12 versus JAK3. |
| CSN16800 | Pyridone 6 | 457081-03-7 | Pyridone 6 is a potent and selective inhibitor of JAK1 (IC5015 nM, murine JAK1), JAK2 (IC501 nM), JAK3 (Ki5 nM), and Tyk2 (IC501 nM) displaying significantly weaker affinities(130 nM to 10 mM) for other protein tyrosine kinases. |
| CSN23211 | ZM 449829 | 4452-06-6 | Potent, selective JAK3 inhibitor |
| CSN19685 | PF-956980 | 1262832-74-5 | PF-956980 is a FGF1 receptor antagonist, a PDGF receptor modulator, an Flt3 tyrosine kinase modulator, and a VEGF antagonist used as immunosuppressive agent. |
| CSN26122 | PF-06826647 | 2127109-84-4 | PF-06826647 is a selective TYK2 inhibitor It is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. |
| CSN23226 | PF-06700841 Tosylate Salt | 2140301-96-6 | PF-06700841 P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. PF-06700841 P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1]. |
| CSN19687 | PF-06263276 | 1421502-62-6 | PF-06263276 is a potent and selective pan-JAK inhibitor which is suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin. |
| CSN16871 | Peficitinib | 944118-01-8 | Peficitinb is an oral Janus kinase (JAK) inhibitor. Peficitinib inhibits JAK1, JAK2, JAK3 and Tyk2 enzyme activities with IC50s of 3.9, 5.0, 0.71 and 4.8 nM, respectively, and has moderate selectivity for JAK3 inhibition. |
| CSN19239 | Oclacitinib Fumarate | 1640292-55-2 | Oclacitinib Fumarate is a potent JAK inhibitor with IC50 value ranging in 10-99 nM for JAK family members, most potent against JAK1 with IC50 value of 10 nM. |
| CSN17137 | NVP-BSK805 | 1092499-93-8 | NVP-BSK805 is a selective JAK2 and JAK2V617F mutant inhibitor with IC50 value of 048 nM with 20-fold selectivity over TYK2 JAK3 and JAK1 IC50 values of 108 187 and 316 nM respectively |
| CSN23010 | NSC 33994 | 82058-16-0 | NSC 33994 is a selective inhibitor of JAK2 with IC50 of 60 nM. |
| CSN23158 | TCS 21311 | 1260181-14-3 | NIBR3049, also known as TCS-21311, is a potent and selective JAK3 inhibitor IC50 values of 8 nM.. |
| CSN11462 | Mollugin | 55481-88-4 | Mollugin, a natural product isolated and purified from the roots of Rubia cordifolia L., may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. |
| CSN11286 | Lestaurtinib | 111358-88-4 | Lestaurtinib is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. |
| CSN23767 | JAK3-IN-6 | 1443235-95-7 | JAK3-IN-6 is an irreversible, potent and highly selective JAK3 inhibitor with IC50 value of 0.15 nM, 4300-fold selective for JAK3 over JAK1 in enzyme assays. |
| CSN22435 | JAK-IN-1 | 1334673-53-8 | JAK-IN-1 is a JAK123 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. |
| CSN20267 | JAK Inhibitor C35 | 1400687-19-5 | JAK inhibitor C6 is a potent dual JAK13 inhibitor providing exceptional biochemical potency against JAK1 and JAK3 while maintaining good selectivity against JAK2 and Tyk2. |
| CSN22434 | JAK Inhibitor 1 | 2096999-92-5 | JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. |
| CSN17204 | Itacitinib | 1334298-90-6 | Itacitinib is an oral selective JAK1 tyrosine kinase inhibitor, which is potential for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis. |
| CSN13689 | GLPG0634 Analog | 1206101-20-3 | GLPG0634 analog is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1JAK2JAK3. |
| CSN23319 | FM381 | 2226521-65-7 | FM381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909 at the gatekeeper position +7 in JAK3. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively. |
| CSN15694 | Filgotinib | 1206161-97-8 | Filgotinib is a selective JAK12 inhibitor with IC50 values of 1028nM, with less potency against JAK3 and TYK2 with IC50 values of 810 nM and 116 nM, respectively. |
| CSN27527 | Fedratinib hydrochloride hydrate | 1374744-69-0 | Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research. |
| CSN21229 | Delgocitinib | 1263774-59-9 | Delgocitinib is a novel and specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. |
| CSN14154 | Dehydrocrenatidine | 65236-62-6 | Dehydrocrenatidine, a natural product isolated and purified from the barks of Picrasma quassioides, is a JAK-specific inhibitor, which inhibits JAK2-JH1 kinase activity in vitro , represses constitutively activated JAK2 and STAT3, as well as interleukin-6-, interferon--, and interferon--stimulated JAK activity, and STAT phosphorylation, and suppresses STAT3 and STAT1 downstream gene expression. |
| CSN13843 | Decernotinib | 944842-54-0 | Decernotinib is a selective JAK3 inhibitor with Ki value of 2.5nM, with 4-fold selectivity over JAK1, JAK2, and TYK2 with Ki values of 11nM, 13nM and 13nM, respectively. |
| CSN17436 | CYT387 Sulfate | 1056636-06-6 | CYT387 sulfate is an ATP-competitive inhibitor of JAK1JAK2 with IC50 of 11 nM18 nM, 10-fold selectivity versus JAK3. |
| CSN13153 | CYT387 | 1056634-68-4 | CYT387 is a selective and potent ATP-competitive JAK1/2 inhibitor with IC50 values of 11nM and 18nM, respectively, with less potency against JAK3 with IC50 value of 155 nM. |
| CSN10079 | Cucurbitacin I | 2222-07-3 | Cucurbitacin I is a naturally occurring triterpenoid derived from Cucurbitaceae family plants that exhibits a number of potentially useful pharmacological and biological activities. |
| CSN16269 | CTX-0294885 | 1439934-41-4 | CTX-0294885 is a bisanilino pyrimidine and exhibits inhibitory activity against a broad range of kinases in vitro, further developed into a Sepharose-supported kinase capture reagent. |
| CSN13905 | Cerdulatinib | 1198300-79-6 | Cerdulatinib is a multiple tyrosine kinase inhibitor with IC50 values of 12 nM6 nM8 nM and 0.5 nM, for JAK1JAK2JAK3 and TYK2, also shows potency against MST1, ARK5, MLK1, Fms. Syk, etc. with IC50 values ranging in 4-51 nM. |
| CSN19204 | Cerdulatinib HCl | 1369761-01-2 | Cerdulatinib HCl is a dual JAKSYK inhibitor with IC50 of 12 nM6 nM8 nM0.5 nM and 32 nM for JAK1JAK2JAK3TYK2 and Syk, respectively. It also inhibits other kinases with IC50 less than 200 nM. |
| CSN15836 | CEP-33779 | 1257704-57-6 | CEP-33779 is a highly selective JAK2 inhibitor with IC50 value of 1.8 nM, with much less potency against JAK1 and TYK2 with 40- and 800-fold IC50 values. |
| CSN17535 | Baricitinib Phosphate | 1187595-84-1 | Baricitinib Phosphate can selectively inhibit JAK12 inhibitor with IC50 values of 5.9 nM and 5.7 nM. |
| CSN13692 | Baricitinib | 1187594-09-7 | Baricitinib can selectively inhibit JAK12 inhibitor with IC50 values of 5.9 nM and 5.7 nM. |
| CSN17120 | AZ 960 | 905586-69-8 | AZ 960 is a potent ATP-competitive JAK inhibitor with IC50 values of 3 nM and 9nM for JAK2 and JAK3 respectively |
| CSN24191 | Abrocitinib | 1622902-68-4 | Abrocitinib is a potent and selective JAK1 inhibitor with IC50s of 29 and 803nM for JAK1 and JAK2, respectively. |
| CSN19970 | Curculigoside | 85643-19-2 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
